Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04789096
Title Tucatinib Together With Pembrolizumab and Trastuzumab (TUGETHER)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Breast Cancer Trials, Australia and New Zealand
Indications

Her2-receptor positive breast cancer

Therapies

Pembrolizumab + Trastuzumab + Tucatinib

Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib

Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
Border Medical Oncology Albury New South Wales 2640 Australia Details
Coffs Harbour Health Campus Coffs Harbour New South Wales 2450 Australia Details
Gosford Hospital Gosford New South Wales 2250 Australia Details
Nepean Cancer Care Centre Kingswood New South Wales 2747 Australia Details
Macquarie University Macquarie Park New South Wales 2109 Australia Details
Prince of Wales Hospital Randwick New South Wales 2031 Australia Details
Calvary Mater Newcastle Waratah New South Wales 2310 Australia Details
Westmead Hospital Westmead New South Wales 2145 Australia Details
Sunshine Coast University Hospital Birtinya Queensland 4575 Australia Details
Royal Adelaide Hospital Adelaide South Australia 5000 Australia Details
Icon Cancer Centre Hobart Hobart Tasmania 7000 Australia Details
Ballarat Health Services (Grampians Health) Ballarat Victoria 3350 Australia Details
Austin Hospital Heidelberg Victoria 3084 Australia Details
Peter MacCallum Cancer Centre Parkville Victoria 3002 Australia Details
Epworth Richmond Hospital Richmond Victoria 3121 Australia Details
Sunshine Hospital St Albans Victoria 3021 Australia Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field